$Early Results from a Phase-2 Study of Varnimcabtagene Autoleucel (IMN-003A), a First-in-India Industry CD19-Directed CAR-T Cell Therapy with Fractionated Infusions for Patients with Relapsed and/or Refractory B Cell Malignancies (IMAGINE Study)$

Early Results from a Phase-2 Study of Varnimcabtagene Autoleucel (IMN-003A), a First-in-India Industry CD19-Directed CAR-T Cell Therapy with Fractionated Infusions for Patients with Relapsed and/or Refractory B Cell Malignancies (IMAGINE Study)

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2022-11, Vol.140 (Supplement 1), p.10343-10344
Hauptverfasser:	Damodar, Sharat, Bhat, Sunil, Nayak, Akshatha, Mallya, Pooja, Ram S, Bharath, Joshi, Ravi, MB, Deepak, Chougule, Sudarshan, Joseph, Anne Roshan, Jakka, Gopinadh, Dhar, Sudeshna, Kumar MG, Arun, Palanisamy, Murugan, Elluru, Sri Ramulu, Akheel, Mohammed Manzoor, Anand, Arun, Kamat, Anil
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!